(Q43808460)

27 November 2017

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

Geir Erland Tjønnfjord

2

object named as

Tjønnfjord GE

1 reference

27 November 2017

1

Berentsen S

1 reference

27 November 2017

8

Ulvestad E

1 reference

27 November 2017

Brudevold R

3

1 reference

27 November 2017

Gjertsen BT

4

1 reference

27 November 2017

Langholm R

5

1 reference

27 November 2017

Løkkevik E

6

1 reference

27 November 2017

Sørbø JH

7

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

British Journal of Haematology

27 November 2017

1 reference

27 November 2017

115

1 reference

27 November 2017

1

1 reference

27 November 2017

79-83

1 reference

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

27 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03078.X

Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03078.X

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03078.X

Acute phase haemolysis in chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03078.X

10.1046/J.1365-2141.2001.03078.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference